Bryan Garnier - 4D Pharma (DDDD) 4D PHARMA (CORPORATE, TP 360p) | H1 2021 results highlight the ongoing progress:

Report

Bryan Garnier

Olga Smolentseva

4D PHARMA (CORPORATE, TP 360p) | H1 2021 results highlight the ongoing progress:

4D PHARMA (CORPORATE, TP 360p) | H1 2021 results highlight the ongoing progress

30/09/2021 3 EN

Underlying

4D Pharma

4D Pharma is engaged in research and development of pharmaceutical products in live biotherapeutic areas.

See profile

GB00BJL5BR07 London Stock Exchange United Kingdom

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Olga Smolentseva

Other Reports on these Companies

Bryan Garnier

Coverage dropped

October 11, 2022 October 11, 2022 1 EN

UOB

China Consumer: Positive RSV recovery in August; four key areas in the consumer space bear watching.

The yoy growth of total RSV was faster in Aug 22 (5.4%) than in Jul 22 (2.7%) on the low base in Aug 21. Despite near-term consumption being largely decided by the pandemic situation, we expect better consumption in 2H22 than in 1H22. We suggest watching four key areas in the consumer space: a) further increase in concentration (eg Jonjee), b) low penetration (eg duty-free), c) easing cost pressure (eg beer), and d) strong pricing power (eg Moutai). Maintain OVERWEIGHT on China’s consumer sector.

September 19, 2022 September 19, 2022 1 EN

BusinessWire

4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma

LEEDS, England--(BUSINESS WIRE)-- 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that in Part B of its signal finding study of MRx0518 in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with solid tumors that have progressed on a prior immune checkpoint inhibitor (ICI), the renal cell carcinoma (RCC) group has met its primary efficacy endpoint ahead of enrollment completion. The ongoing study is being conducted in...

March 23, 2022 March 23, 2022 1 EN

Cinclus: agreement with the FDA on the iPSP

Similar to the agreement for the PIP concluded with the EU's EMA a couple of weeks ago, Cinclus has reached an agreement with the FDA on the company’s initial Paediatric Study Plan (iPSP) for linaprazan glurate, which is a prerequisite for market approval for adult use in the US. The study plan wil

November 22, 2024 November 22, 2024 1 EN

Maria Vara

Maria Vara

BICO: divests Nanoscribe for EUR26m in line with BICO 2.0 Strategy

BICO has agreed to sell Nanoscribe to LAB14 GmbH for an equity value of EUR26m (SEK294m), with the transaction set to close in Q4 2024. We are pleased to see the company executing the BICO 2.0 strategy shared during CMD 2024, which designates Nanoscribe as non-core due to its primary focus outside

November 22, 2024 November 22, 2024 1 EN

Aurelien Deside

Aurelien Deside

Exclusive Networks: expanding into the US with Cloudrise acquisition

Yesterday evening, Exclusive Networks announced the acquisition of 100% of Cloudrise, a security services provider headquartered in the USA. This acquisition represents a positive step towards the continued penetration of the highly attractive US cybersecurity market, which the group sees as a key

November 22, 2024 November 22, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

4D PHARMA (CORPORATE, TP 360p) | H1 2021 results highlight the ongoing progress:

Coverage dropped

China Consumer: Positive RSV recovery in August; four key areas in the consumer space bear watching.

4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma

Cinclus: agreement with the FDA on the iPSP

BICO: divests Nanoscribe for EUR26m in line with BICO 2.0 Strategy

Exclusive Networks: expanding into the US with Cloudrise acquisition

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe